Yuxian Bai

机构：Harbin Medical University, Third Affiliated Hospital of Harbin Medical University · ORCID：0000-0002-5004-7523

发表论文 348 篇 · 总被引 19685 次 · h-index 59

代表论文

• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (2025 · Journal of Clinical Oncology · 被引 44)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 24)
• Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study (2025 · Current Medical Research and Opinion · 被引 5)
• Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial (2025 · Cancer Immunology Immunotherapy · 被引 3)
• KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (2025 · Journal of Clinical Oncology · 被引 3)